Paired plasma lipidomics and proteomics analysis in the conversion from mild cognitive impairment to Alzheimer's disease
-
Published:2024-06
Issue:
Volume:176
Page:108588
-
ISSN:0010-4825
-
Container-title:Computers in Biology and Medicine
-
language:en
-
Short-container-title:Computers in Biology and Medicine
Author:
Gómez-Pascual AliciaORCID, Naccache Talel, Xu Jin, Hooshmand Kourosh, Wretlind AsgerORCID, Gabrielli Martina, Lombardo Marta Tiffany, Shi Liu, Buckley Noel J., Tijms Betty M., Vos Stephanie J.B., ten Kate Mara, Engelborghs SebastiaanORCID, Sleegers KristelORCID, Frisoni Giovanni B., Wallin Anders, Lleó Alberto, Popp JuliusORCID, Martinez-Lage Pablo, Streffer Johannes, Barkhof FrederikORCID, Zetterberg HenrikORCID, Visser Pieter Jelle, Lovestone Simon, Bertram LarsORCID, Nevado-Holgado Alejo J., Gualerzi Alice, Picciolini Silvia, Proitsi PetroulaORCID, Verderio Claudia, Botía Juan A.ORCID, Legido-Quigley CristinaORCID
Reference55 articles.
1. Mild cognitive impairment;Gauthier;Lancet,2006 2. Worldwide prevalence of mild cognitive impairment among community dwellers aged 50 years and older: a meta-analysis and systematic review of epidemiology studies;Bai;Age Ageing,2022 3. Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal;Roberts;Neurology,2014 4. Alzheimer's disease neuroimaging Initiative, predicting Short-term MCI-to-AD progression using imaging, CSF, Genetic factors, cognitive Resilience, and demographics;Varatharajah;Sci. Rep.,2019 5. Predicting MCI outcome with clinically available MRI and CSF biomarkers;Heister;Neurology,2011
|
|